Page 5 - Thomas Biegi News Today

Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 Monjuvi U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9

EQS-News: MorphoSys AG / Key word(s): MiscellaneousLucinda Crabtree to Join MorphoSys as Chief Financial Officer 14.03.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, March 14, 2023 Lucinda Crabtree to Join MorphoSys as Chief Finan...

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost

EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 Morp...

EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  Planegg/Munich, G...

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial

EQS-News: MorphoSys AG / Key word(s): Miscellaneous Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.20...

EQS-News: MorphoSys AG / Key word(s): MiscellaneousChief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, December 20, 2022 Chief Financial Officer Sung Lee to Leave...

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022 10.12.2022 / 23:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  PLANEGG/MUNICH, Germa...

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022  11.12.2022 / 23:31 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  ...